Pregabalin for the treatment of generalized anxiety disorder: an update

Simple item page
dc.contributor.authorBaldwin, David S
dc.contributor.authorAjel, Khalil
dc.contributor.authorMasdrakis, Vasilios G
dc.contributor.authorNowak, Magda
dc.contributor.authorRafiq, Rizwan
dc.date.accessioned2021-10-08T07:08:27Z
dc.date.available2021-10-08T07:08:27Z
dc.date.issued2013
dc.description.abstractA previous review summarized what was then known about the potential role of pregabalin in the treatment of patients with generalized anxiety disorder (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in “over-excited” presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD.
dc.identifier.apacitationBaldwin, D. S., Ajel, K., Masdrakis, V. G., Nowak, M., & Rafiq, R. (2013). Pregabalin for the treatment of generalized anxiety disorder: an update. <i>Neuropsychiatric Disease and Treatment</i>, 49(4), 883 - 177. http://hdl.handle.net/11427/34584en_ZA
dc.identifier.chicagocitationBaldwin, David S, Khalil Ajel, Vasilios G Masdrakis, Magda Nowak, and Rizwan Rafiq "Pregabalin for the treatment of generalized anxiety disorder: an update." <i>Neuropsychiatric Disease and Treatment</i> 49, 4. (2013): 883 - 177. http://hdl.handle.net/11427/34584en_ZA
dc.identifier.citationBaldwin, D.S., Ajel, K., Masdrakis, V.G., Nowak, M. & Rafiq, R. 2013. Pregabalin for the treatment of generalized anxiety disorder: an update. <i>Neuropsychiatric Disease and Treatment.</i> 49(4):883 - 177. http://hdl.handle.net/11427/34584en_ZA
dc.identifier.issn1176-6328
dc.identifier.issn1178-2021
dc.identifier.ris TY - Journal Article AU - Baldwin, David S AU - Ajel, Khalil AU - Masdrakis, Vasilios G AU - Nowak, Magda AU - Rafiq, Rizwan AB - A previous review summarized what was then known about the potential role of pregabalin in the treatment of patients with generalized anxiety disorder (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in “over-excited” presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD. DA - 2013 DB - OpenUCT DP - University of Cape Town IS - 4 J1 - Neuropsychiatric Disease and Treatment LK - https://open.uct.ac.za PY - 2013 SM - 1176-6328 SM - 1178-2021 T1 - Pregabalin for the treatment of generalized anxiety disorder: an update TI - Pregabalin for the treatment of generalized anxiety disorder: an update UR - http://hdl.handle.net/11427/34584 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34584
dc.identifier.vancouvercitationBaldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatric Disease and Treatment. 2013;49(4):883 - 177. http://hdl.handle.net/11427/34584.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Psychiatry and Mental Health
dc.publisher.facultyFaculty of Health Sciences
dc.sourceNeuropsychiatric Disease and Treatment
dc.source.journalissue4
dc.source.journalvolume49
dc.source.pagination883 - 177
dc.source.urihttps://dx.doi.org/10.2147/NDT.S36453
dc.subject.otherDOAJ:Health Sciences
dc.subject.otherRC321-571
dc.subject.otherDOAJ:Medicine (General)
dc.subject.otherInternal medicine
dc.subject.otherpregabalin
dc.subject.otherefficacy
dc.subject.otherReview
dc.subject.othergeneralized anxiety disorder
dc.subject.othertolerability
dc.subject.otherR
dc.subject.otherRC31-1245
dc.subject.otherMedicine
dc.subject.otherNeurosciences. Biological psychiatry. Neuropsychiatry
dc.subject.otherDOAJ:Neurology
dc.titlePregabalin for the treatment of generalized anxiety disorder: an update
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
BaldwinDavidS_Pregabalin_for_2013.pdf
Size:
195.57 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles